about
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Quantifying factors for the success of stratified medicine.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Expression of NRG1 and its receptors in human bladder cancer.Pharmacogenetics in drug development.Pharmacogenetics and drug development: the path to safer and more effective drugs.Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences.Pulmonary toxicity from novel antineoplastic agents.Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform.Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaImproving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCProduction of therapeutic antibodies with controlled fucosylation.A statistician's perspective on biomarkers in drug development.Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.Delay to formalin fixation effect on breast biomarkers.Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.Activated Stat-3 in Melanoma
P2860
Q33236634-0480D5EC-10F2-45BC-9D4F-13BBC019FD0AQ33394650-70092B93-F31F-4665-8234-04339FECB300Q33410392-7A44C688-CA72-477F-BD20-6A5D5D4C8F4EQ34228544-E0AE3129-2217-438A-BD79-E951046DFDDFQ34574834-61E479FA-F7DA-429B-84C0-C5CF52E7CDBCQ34745805-843A276E-545D-4A17-85CD-5CDCF7DCF512Q35038056-558E4B7B-55E3-40E4-862B-1EA33ADB367CQ35889605-C634291E-2A74-4A75-ACD0-ADB26B765D77Q36230879-C74BE091-3822-488F-8252-A58D0ED69D4EQ36314452-90E8238F-5C4F-41F7-A065-02D3141F2DF7Q36412671-57BF33B1-B679-4786-8F35-45869CE22072Q37269115-6D2C7F90-267D-407D-8383-16CE0A7C37DAQ37323537-05BA7FB9-1770-4442-81DB-B33B31CCEE00Q37351498-EDF0ED65-0E1B-469F-AB88-F5F337269DFDQ37403194-14913F51-036D-4CA1-98A4-5DC1A8FF6D78Q37672128-B77B3155-686F-4C28-BA89-1E791DD6003BQ37967642-84D0727E-2672-4EA7-8B13-5141B6BD06EAQ40557870-9F93301C-59D4-4511-948F-8D8F699640C7Q43280139-91153980-C8A7-4738-9361-61C23DDD971AQ44211870-059E7194-1FB8-474E-AC31-E6069F552EF4Q56032135-3DF21B04-01B1-4F11-A31B-8DE27AF26BCE
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical experience with trastuzumab (herceptin).
@ast
Clinical experience with trastuzumab (herceptin).
@en
type
label
Clinical experience with trastuzumab (herceptin).
@ast
Clinical experience with trastuzumab (herceptin).
@en
prefLabel
Clinical experience with trastuzumab (herceptin).
@ast
Clinical experience with trastuzumab (herceptin).
@en
P2860
P1433
P1476
Clinical experience with trastuzumab (herceptin).
@en
P2093
Charles L Vogel
Sandra X Franco
P2860
P304
P356
10.1046/J.1524-4741.2003.09602.X
P577
2003-11-01T00:00:00Z